The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
white-paper
The Potential Impact of U.S. Tariffs on the Biotech Sector: Manufacturing, Funding, and Clinical Trials
Read More
post
Leveraging FDA Type A Meetings for Faster Drug Development
Read More
post
Pharmaceutical Drug Development Process: How New Medications Are Brought to Patients
Read More
white-paper
Regulatory Overview of Combination Products
Read More
Let's move from science to success.
Let’s Talk